Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Neurodegeneration Biomarkers in Patients with Subjective Cognitive Complaints

    In individuals with subjective cognitive decline, multiple biomarkers of neurodegeneration were found to add predictive values beyond amyloid and tau biomarkers; however, the various neurodegeneration biomarkers were not equivalent and should not be used interchangeably.

  • Antibody Profile in Refractory Myasthenia Gravis

    In retrospective studies of patients with generalized myasthenia gravis, those who are refractory to multiple treatments have disease onset at an earlier age, are more likely to have thymic pathology, and are more likely to be double-seronegative (neither acetylcholine receptor nor muscle-specific receptor tyrosine kinase antibodies).

  • Outcomes of Progressive Multifocal Leukoencephalopathy Treated with IL-7

    Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system caused by the reactivation of the JC virus. The authors of this study conducted a multi-centered retrospective observational study on 64 patients with PML who were treated with recombinant human IL-7 (RhIL-7). Overall, the one-year all-cause survival following start of RhIL-7 was 55% and similar among human immunodeficiency virus/acquired immunodeficiency syndrome, hematological malignancies, and primary immunodeficiencies.

  • Does Amantadine Treatment Reduce Levodopa-Induced Dyskinesias?

    This retrospective cohort study compared the effect of amantadine on levodopa-induced dyskinesia (LID) onset with use of anticholinergics and monoamine oxidase type B inhibitors in patients with Parkinson’s disease. The authors concluded that early treatment with amantadine may delay LID onset more than treatment with other symptomatic agents.

  • Cognitive Outcomes After Mild Traumatic Brain Injury

    Mild traumatic brain injuries (mTBIs) may lead to adverse cognitive and neuropsychiatric outcomes. The pathways that lead to adverse cognitive outcomes remain to be scientifically elucidated. A prospective cohort study of 656 participants enrolled in the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) study found that at one year, 13.5% of participants with mTBI had poor cognitive outcome compared to 4.5% of controls, highlighting the need for better understanding of the mechanisms leading to poor cognitive and functional outcomes after mTBIs and interventions to optimize cognitive recovery.

  • Identifying Community-Acquired Pneumonia During the COVID-19 Pandemic

    Pneumonia is an infection of the alveoli of the lungs. Alveolar infection results in inflammation that disrupts normal pulmonary function, producing impaired gas exchange. Pneumonia can be caused by bacteria, viruses, or fungi. Pathogens can infect the lung parenchyma through three routes: inhalation, aspiration, or hematogenous spread. In community-acquired pneumonia, the infection is initiated outside the hospital. The prevalence of COVID-19, the clinical disease caused by the SARS-CoV-2 virus, has changed the landscape of pneumonia.

  • Long COVID: The Winding Road Back

    Clinical experts working with healthcare professionals who have acquired long COVID say it can be a hard road returning to work, but rehabilitation models used for other chronic conditions are proving helpful.

  • COVID-19 Vaccine Protects Mothers, Newborns

    COVID-19 vaccination and pregnancy issues have been clouded by misinformation, leading women who are pregnant or trying to become pregnant to decline immunization. The accumulating evidence strongly suggests vaccination safeguards pregnant women against severe infection and also confers protective immunity to the newborn baby.

  • White House Targets Long COVID with Major Interagency Initiative

    The Biden administration has launched a major initiative to better understand and treat long COVID, which manifests as brain fog, fatigue, and a panoply of other lingering symptoms in those with SARS-CoV-2.

  • OSHA Finalizing COVID-19 Rule in Healthcare Settings

    Under the CDC's current guidance for healthcare workers, many requirements for those workers are triggered based on the level of community transmission of COVID-19. Such an approach would create the flexibility many have been calling for, which have come with the warning that requirements set in regulatory stone could quickly be outdated by the changing nature of the pandemic.